Key pharmaceutical and academic leaders in idiopathic pulmonary fibrosis (IPF) will gather at the Third Annual IPF Summit in San Diego to discuss the latest developments in the field. The conference, taking place Aug. 27-29, aims to create a discussion and networking environment to overcome the translational gap…
2019 IPF Summit Continues Previous Year’s Work to Advance Therapies
In the age of social media, many people seem to have forgotten what healthy boundaries are. If you use Facebook, for example, you may notice that some people overshare — whether it’s 200 pictures of their trip to the beach or details of their child’s bowel movements, they demonstrate little…
The use of oxygen at rest is associated with a greater likelihood of death or lung transplant in people with idiopathic pulmonary fibrosis (IPF), a study shows. The results also showed that lower lung function at the start of the study, as measured by tests like forced vital…
Monday, June 3 was a difficult day for the pulmonary fibrosis (PF) community. An advocate, colleague, and friend passed away from complications of PF, but even in her death, Kim Fredrickson will continue to inspire many living with this life-threatening lung disease. While her loss is felt deeply in…
In the past week, two people have passed with whom I am familiar. One of them is well-known in the pulmonary fibrosis community; the other is a close family friend. Pulmonary Fibrosis News columnist Kim Fredrickson was a wonderful person and a passionate advocate. I read her columns and kept…
Increased levels of specific proteins found in blood, namely C-reactive protein, lactate dehydrogenase, and total cholesterol, may predict the risk of mortality after acute exacerbation in idiopathic pulmonary fibrosis (IPF) patients, according to a retrospective study performed in Japan. The study, “Possible Serological Markers to Predict…
Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy for idiopathic pulmonary fibrosis (IPF). Currently approved therapies for IPF can slow disease progression, but cannot restore…
An exploratory Phase 2 study of Prometic‘s investigative oral therapy PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF) showed “encouraging” results and no safety concerns, a study reports. Alone or in combination with Ofev (nintedanib), PBI-4050 was well-tolerated and showed…
The path to lung transplant is different for everyone, depending on their disease and how it progresses. My mom got very sick very fast. I found out that she would try to get listed, and 10 stressful weeks later, she had new lungs. What may be an extended…
As many as one in four people with idiopathic pulmonary fibrosis (IPF) may have the illness as a result of inhaling vapors, gas, dust, or fumes at work, according to an official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Such occupational…
